SCHEMBL23330833

SCHEMBL23330833

COCCC(=O)Nc1cnc(Cl)nc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLS O94925 2/20 0.38
THRB P10828 1/20 0.38
POLB P06746 1/20 0.38
KDR P35968 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK10 P53779 1/20 0.38
P2RX3 P56373 1/20 0.38
BRAF P15056 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB1 P19838 3/20 0.36
JUN P05412 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
ATF1 P18846 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
HPGD P15428 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23330674 0.85 ALDH1A1 (0.48) POLBKMT2ASMN1; SMN2HPGDALDH1A1
SCHEMBL23330868 0.85 CHEK1 (0.44) POLBNFKB1JUNNFKB2RELA
SCHEMBL23330835 0.84 BRAF (0.36) GLSTHRBPOLBKDRMAPK8
SCHEMBL17385135 0.80 MEN1 (0.44) THRBNPC1RAB9ANFKB1JUN
SCHEMBL23330824 0.78 NFKB1 (0.42) NFKB1JUNNFKB2RELAATF1
SCHEMBL23331269 0.75 MEN1 (0.64) POLBNPC1RAB9ANFKB1NFKB2
SCHEMBL23331258 0.75 PTK2 (0.43) POLBNFKB1JUNNFKB2RELA
SCHEMBL23330667 0.74 ABL1 (0.41) POLBMEN1KMT2AALDH1A1
SCHEMBL17111799 0.73 NFKB1 (0.40) NFKB1JUNNFKB2RELAATF1
SCHEMBL23331244 0.72 P2RX7 (0.43) POLBNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 US disclosed
WO-2021083380-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海科技大学 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 GLS 888/4885THRB 3031/4885POLB 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.